



NIH funding opportunities



Faculty of Medicine and Health Sciences: Research Development and Support 11 Mar 2019 (#8)

[Click on blue [hyperlink](#) for further information]

The NIH funding opportunities listed below are only a **selection** of pre-screened, currently open health funding opportunities for which **South African institutions are eligible to apply**. For a comprehensive selection of NIH funding opportunities, please visit www.grants.nih.gov or www.sun.ac.za/RDSfunding (current & archive).

Confirm your intent to apply ASAP, but not later than 60 days before the submission date.

Contact: RGMO Pre-Awards cdevries@sun.ac.za

Important Notices & News

- The American Society of Human Genetics (ASHG) is partnering with the National Human Genome Research Institute (NHGRI) at NIH and Human Heredity and Health in Africa (H3Africa) to add 25 awards to its annual [Developing Country Awards Program](#). The program will enable 25 genetics trainees and early- to mid-career investigators from Africa who are currently working in Africa to attend the ASHG 2019 Annual Meeting, the world's largest genetics meeting, 15-19 October 2019, Houston, Texas. To be considered for an award, interested applicants must submit an abstract to the ASHG 2019 Annual Meeting by the application deadline 6 June 2019. The applicant must be a citizen of and currently working in a country in Africa categorized by the World Bank as having a low-income or lower-middle-income economy (LMIC). Priority will be given to members of underrepresented groups who have not attended the ASHG meeting in the past and who do not have other resources with which to attend. The ASHG Program Committee will score all abstracts and select the 25 eligible applicants with the highest abstract scores to receive the award. Each awardee will receive travel support through the H3Africa program of up to \$3,000 and complimentary registration to the ASHG 2019 Annual Meeting.
- [Uploading Studies to ClinicalTrials.gov Just Got Easier](#) When conducting clinical trials, NIH funding recipients are required to register their study at ClinicalTrials.gov. To make registration easier, a new feature in the eRA Human Subjects System (HSS) allows applicants and recipients to export study record entries as an XML file, and upload fields that are captured in both systems directly into ClinicalTrials.gov's Protocol Registration and Results System (PRS).
- [Keep Filenames in Grant Applications Short and Sweet](#) Attaching a file to your grant application? Make sure the filename is under 50 characters
- [For Your Renewal Application: Mind the Cap](#) Remember when planning the budget for your next renewal application that NIAID caps R01 renewal budgets at 20 percent over the direct costs of the last noncompeting award, excluding several categories of costs.
- HEAL Initiative: Announcement of Collaboration Opportunities for Developing Drugs and Human Cell-Based Testing Platforms for Pain, Addiction and Overdose ([NOT-TR-19-018](#))

1. Next Generation Multipurpose Prevention Technologies (NGM) (Clinical Trial Optional)

Letter of Intent: 30 days prior to the application due date

Hyperlink: [\(PAR-19-209\)](#)

Type: R01

Application Due Date: May 6, 2019; May 6, 2020; May 6, 2021 Apply by 5:00 PM local time of applicant organization.

Funding Opportunity Announcement: The objective of this Funding Opportunity Announcement (FOA) is to support the development of new and innovative on-demand, event-driven and long-acting systemic and non-systemic multipurpose prevention technologies (MPT). It supports development of MPTs that prevent HIV infection and pregnancy (hormonal and non-hormonal methods); sexually transmitted infections (STI) and pregnancy, and (HIV/STI) and non-HIV STI MPTs in cis and trans males and females of all ages. Applications for MPT development may involve pharmacokinetic (PK), pharmacodynamic (PD), safety and, drug-drug interactions (DDI) studies using drug development and formulation science supported by animal model testing. Also supported are biobehavioral and behavioral/social studies to identify MPT user-desired rheological and biophysical factors (look, feel, effectiveness, safety and duration of action) and other behavioral/social factors that could promote increased MPT adoption and use.

Budget: Application budgets are not limited but need to reflect the actual needs of the proposed project. The scope of the proposed project should determine the project period. The maximum project period is 5 years.

2. Emerging Infectious Diseases Research Centers (Clinical Trial Not Allowed)

Letter of Intent: 30 days prior to the application due date

Hyperlink: [\(RFA-AI-19-028\)](#)

Type: U01

Application Due Date: June 28, 2019. Apply by 5:00 PM local time of applicant organization.

Funding Opportunity Announcement: The purpose of this Funding Opportunity Announcement (FOA) is to establish a coordinated network of Emerging Infectious Disease Research Centers (EIDRCs) in regions around the globe where emerging and re-emerging infectious disease outbreaks are likely to occur. Multidisciplinary teams of investigators will conduct pathogen/host surveillance, study pathogen transmission, including evaluating zoonotic hosts and reservoirs, study pathogenesis and immunologic responses in the host, and will develop reagents and diagnostic assays for improved detection for important emerging pathogens and their vectors. These EIDRC will conduct research project(s) and will collaborate under the direction of a separate EIDRC Coordinating Center (EIDRC CC, [\(RFA-AI-19-029\)](#)), to develop and formulate strategies for detecting, controlling and preventing emergence or re-emergence of infectious diseases. Rapid translation of these findings to development of reagents, diagnostic tools, etc. that will be provided to downstream partners to advance therapeutic and preventive interventions is key. Pathogens already studied by other NIAID funded networks, such as influenza, tuberculosis, malaria and antibiotic resistant bacteria. Please contact the Scientific/Research Contact if further clarification is needed.

Budget: NIAID intends to commit \$6M in FY 2020 to fund 2-4 awards. Applications budget are limited to up to \$850,000 per year in direct costs and need to reflect the actual needs of the proposed project. The scope of the proposed project should determine the project period. The maximum period is 5 years.

3. Next Generation Multipurpose Prevention Technologies (NGM) (Clinical Trial Optional)

Letter of Intent: 30 days prior to the application due date

Hyperlink: [\(PAR-19-209\)](#)

Type: R01

Application Due Date: May 6, 2019; May 6, 2020; May 6, 2021 Apply by 5:00 PM local time of applicant organization.

Funding Opportunity Announcement: The objective of this Funding Opportunity Announcement (FOA) is to support the development of new and innovative on-demand, event-driven and long-acting systemic and non-systemic multipurpose prevention technologies (MPT). It supports development of MPTs that prevent HIV infection and pregnancy (hormonal and non-hormonal methods); sexually transmitted infections (STI) and pregnancy, and (HIV/STI) and non-HIV STI MPTs in cis and trans males and females of all ages. Applications for MPT development may involve pharmacokinetic (PK), pharmacodynamic (PD), safety and, drug-drug interactions (DDI) studies using drug development and formulation science supported by animal model testing. Also supported are biobehavioral and behavioral/social studies to identify MPT user-desired rheological and biophysical factors (look, feel, effectiveness, safety and duration of action) and other behavioral/social factors that could promote increased MPT adoption and use.

Budget: Application budgets are not limited but need to reflect the actual needs of the proposed project. The scope of the proposed project should determine the project period. The maximum project period is 5 years.

4. Behavioral and Integrative Treatment Development Program (Clinical Trial Optional)

Letter of Intent: 30 days prior to the application due date

Hyperlink: [\(PAR-19-212\)](#)

Type: R01

Application Due Date: July 23, 2019; March 23, 2020; July 23, 2020; March 23, 2021, July 23, 2021, March 23, 2022 Apply by 5:00 PM local time of applicant organization.

Funding Opportunity Announcement: The purpose of this funding opportunity announcement (FOA) is to encourage behavioral intervention development research. Specifically, test efficacy, conduct clinical trials, examine mechanisms of behavior change, determine dose-response, treatment optimization, and/or ascertain best sequencing of behavioral, combined, sequential, or integrated behavioral and pharmacological treatments. Research of interest includes but is not limited to Stage II and Stage III efficacy research, including: (1) drug abuse treatment interventions, including interventions for patients with comorbidities; (2) drug abuse treatment and adherence interventions; (3) drug abuse treatment and adherence interventions that utilize technologies to boost effects and increase implementability and sustainability; (4) interventions to prevent the acquisition or transmission of HIV infection among individuals in drug abuse treatment; (5) interventions to promote adherence to drug abuse treatment, HIV and addiction medications; and (6) interventions to treat substance misuse and chronic pain.

Budget: Application budgets are not limited but need to reflect the actual needs of the proposed project. The maximum project period is 5 years.

5. Behavioral and Integrative Treatment Development Program (Planning Grant, Clinical Trial Optional)

Letter of Intent: 30 days prior to the application due date

Hyperlink: [\(PAR-19-213\)](#)

Type: R34

Application Due Date: July 23, 2019; March 23, 2020; July 23, 2020; March 23, 2021, July 23, 2021, March 23, 2022. Apply by 5:00 PM local time of applicant organization.

Funding Opportunity Announcement: The purpose of this funding opportunity announcement (FOA) is to encourage behavioral intervention development research. Specifically, test efficacy, conduct clinical trials, examine mechanisms of behavior change, determine dose-response, treatment optimization, and/or ascertain best sequencing of behavioral, combined, sequential, or integrated behavioral and pharmacological treatments. Research of interest includes but is not limited to Stage I research, including: (1) drug abuse treatment interventions, including interventions for patients with comorbidities; (2) drug abuse treatment and adherence interventions; (3) drug abuse treatment and adherence interventions that utilize technologies to boost effects and increase implementability and sustainability; (4) interventions to prevent the acquisition or transmission of HIV infection among individuals in drug abuse treatment; (5) interventions to promote adherence to drug abuse treatment, HIV and addiction medications; and (6) interventions to treat substance misuse and chronic pain.

Budget: Direct costs are limited to \$450,000 over a 3-year project period, with no more than \$225,000 in direct costs allowed in any single year. The maximum project period is 3 years.

6. Novel Assays to Address Translational Gaps in Treatment Development (Clinical Trial Optional)

Letter of Intent: 30 days prior to the application due date

Hyperlink: [\(PAR-19-214\)](#)

Type: UG3/UH3

Application Due Date: June 20, 2019, October 18, 2019, February 20, 2020, June 19, 2020, October 20, 2020, February 19, 2021, June 21, 2021, October 20, 2021, February 21, 2022. Apply by 5:00 PM local time of applicant organization.

Funding Opportunity Announcement: National Institute of Mental Health (NIMH) The overall goal of this initiative is to identify neurophysiological measures as potential assays for treatment development research. The funding opportunity announcement (FOA) will support efforts to optimize and evaluate measures of neurophysiological processes that are disrupted within or across mental disorders in both healthy humans and in another species relevant to the therapeutic development pipeline. The initiative will support initial proof of concept studies aimed at identifying measures for potential development as preclinical assays for evaluating potential new drug and device therapies and their targets. Data will also reveal assay measures where the performance between preclinical animal species and humans is dissimilar, thus establishing a firm basis for limiting speculative extrapolations of preclinical animal findings to humans. The ultimate practical goal of this FOA is to improve the efficiency of the therapeutic development process by identifying coherence of measures and inconsistencies between the preclinical screening pipeline and clinical evaluation of new treatment candidates and thereby hasten the development of more effective treatments for mental disorders. The objectives of the FOA will be accomplished by supporting partnerships among basic and translational neuroscientists who are committed to advancing the discovery of in vivo physiological measures as tools for target validation and therapeutic development. Groups will be tasked with developing and optimizing in vivo assays of brain processes in both animals and in healthy humans. Groups will evaluate assay performance across both species in response to specific chemical, physiological, or behavioral manipulations. In this way, projects will reveal the potential of specific assays to translate from animals to humans, suggesting assays for further development as tools in the treatment development pipeline.

Budget: Application budgets are not limited but need to reflect the actual needs of the proposed project. The UG3 period may be 1 or 2 years, the UH3 period may not exceed 3 years. The total duration of the UG3 and UH3 phases may not exceed 4 years.

7. Progression Markers for Cognitive Impairment in Parkinson's Disease Dementia (Clinical Trial Not Allowed)

Letter of Intent: 30 days prior to the application due date

Hyperlink: [\(PAS-19-210\)](#)

Type: R01

Application Due Date: [Standard dates](#) & [Standard AIDS dates](#) Apply by 5:00 PM local time of applicant organization.

Funding Opportunity Announcement: The goal of this Funding Opportunity Announcement (FOA) is to encourage applications that propose to identify biomarkers for onset and progression of cognitive impairment in Parkinson's Disease (PD) through Parkinson's Disease Dementia (PDD). The use of well-characterized populations of PD and PDD patients that have been, and can continue to be, followed longitudinally with clinical assessments and biospecimen collection to autopsy should be considered.

Budget: NIH intends to fund an estimate of 5-7 awards, corresponding to a total of \$5,000,000, for fiscal year 2019. Future year amounts will depend on annual appropriations. Application budgets are not limited but need to reflect the actual needs of the proposed project. The scope of the proposed project should determine the project period. The maximum project period is 5 years.

Brief definitions of some NIH grant mechanisms: [comprehensive list of extramural grant and cooperative agreement activity codes](#)